The European Commission has approved the combination of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the up-front treatment of adult patients with metastatic non–small cell lung cancer without a sensitizing EGFR mutation or an ALK translocation.
The European Union has approved olaparib in combination with bevacizumab for use as a first-line maintenance treatment in patients with homologous recombination deficient–positive advanced ovarian cancer.
The European Commission has approved the combination of atezolizumab plus bevacizumab for use in adult patients with advanced or unresectable hepatocellular carcinoma who have not been given previous systemic therapy.
The China National Medical Products Administration has approved the combination of atezolizumab plus bevacizumab for use in patients with unresectable hepatocellular carcinoma who have not received previous systemic therapy.
The European Commission has approved niraparib for use as a frontline monotherapy maintenance option in adult patients with advanced epithelial, high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response after platinum-based chemotherapy.
A supplemental application was submitted to the Japanese Ministry of Health, Labour, and Welfare for Manufacturing and Marketing approval of the combination of cabozantinib plus nivolumab for the treatment of patients with unresectable, advanced, or metastatic renal cell carcinoma.
Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.
Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.
Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.
Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.
New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.
Nicole Concin, MD, discusses the rationale for the phase 1/2 LIO-1 trial in advanced gynecologic malignancies.
Patricia Pautier, MD, discusses limitations in leiomyosarcoma.
The combination of bavituximab and pembrolizumab demonstrated synergistic antitumor activity and was well tolerated in patients with pretreated advanced gastric or gastroesophageal junction cancer.
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.
Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.
Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.
Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.
John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.
